These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 37994573)
1. A Complement to Traditional Treatments for Antibody-Mediated Rejection? Use of Eculizumab in Lung Transplantation: A Review and Early Center Experience. Kleiboeker HL; Prom A; Paplaczyk K; Myers CN Ann Pharmacother; 2024 Sep; 58(9):947-955. PubMed ID: 37994573 [TBL] [Abstract][Full Text] [Related]
3. Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases. Tan EK; Bentall A; Dean PG; Shaheen MF; Stegall MD; Schinstock CA Transplantation; 2019 Nov; 103(11):2397-2404. PubMed ID: 30801549 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Yamamoto T; Watarai Y; Futamura K; Okada M; Tsujita M; Hiramitsu T; Goto N; Narumi S; Takeda A; Kobayashi T Transplant Proc; 2017; 49(1):159-162. PubMed ID: 28104125 [TBL] [Abstract][Full Text] [Related]
5. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. Glotz D; Russ G; Rostaing L; Legendre C; Tufveson G; Chadban S; Grinyó J; Mamode N; Rigotti P; Couzi L; Büchler M; Sandrini S; Dain B; Garfield M; Ogawa M; Richard T; Marks WH; Am J Transplant; 2019 Oct; 19(10):2865-2875. PubMed ID: 31012541 [TBL] [Abstract][Full Text] [Related]
7. Complement-Based Therapy in the Management of Antibody-Mediated Rejection. Bhalla A; Alachkar N; Alasfar S Adv Chronic Kidney Dis; 2020 Mar; 27(2):138-148. PubMed ID: 32553246 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. Marks WH; Mamode N; Montgomery RA; Stegall MD; Ratner LE; Cornell LD; Rowshani AT; Colvin RB; Dain B; Boice JA; Glotz D; Am J Transplant; 2019 Oct; 19(10):2876-2888. PubMed ID: 30887675 [TBL] [Abstract][Full Text] [Related]
9. The use of eculizumab in renal transplantation. Barnett AN; Asgari E; Chowdhury P; Sacks SH; Dorling A; Mamode N Clin Transplant; 2013; 27(3):E216-29. PubMed ID: 23516966 [TBL] [Abstract][Full Text] [Related]
10. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases. Nester CM; Brophy PD Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of eculizumab-treated positive crossmatch recipients: Allograft survival, histologic findings, and natural history of the donor-specific antibodies. Schinstock CA; Bentall AJ; Smith BH; Cornell LD; Everly M; Gandhi MJ; Stegall MD Am J Transplant; 2019 Jun; 19(6):1671-1683. PubMed ID: 30412654 [TBL] [Abstract][Full Text] [Related]
12. Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients. Jordan SC; Choi J; Kahwaji J; Vo A Transplant Proc; 2016 Apr; 48(3):806-8. PubMed ID: 27234741 [TBL] [Abstract][Full Text] [Related]
14. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria. Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648 [TBL] [Abstract][Full Text] [Related]
15. Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome- a single center experience. Kant S; Bhalla A; Alasfar S; Alachkar N BMC Nephrol; 2020 May; 21(1):189. PubMed ID: 32434487 [TBL] [Abstract][Full Text] [Related]
16. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. Law YM; Nandi D; Molina K; Gambetta K; Daly KP; Das B Cardiol Young; 2020 Jan; 30(1):107-113. PubMed ID: 31875805 [TBL] [Abstract][Full Text] [Related]
17. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. Yerly P; Rotman S; Regamey J; Aubert V; Aur S; Kirsch M; Hullin R; Pascual M Xenotransplantation; 2022 Jan; 29(1):e12726. PubMed ID: 35001433 [TBL] [Abstract][Full Text] [Related]
18. Eculizumab use in kidney transplantation. Johnson CK; Leca N Curr Opin Organ Transplant; 2015 Dec; 20(6):643-51. PubMed ID: 26536427 [TBL] [Abstract][Full Text] [Related]
19. Upfront use of eculizumab to treat early acute antibody-mediated rejection after kidney allotransplantation and relevance for xenotransplantation. Schwotzer N; Paganetti G; Barchi M; Perrottet N; Aubert V; Sadallah S; Rotman S; Venetz JP; Matter M; Golshayan D; Pascual M Xenotransplantation; 2020 Jul; 27(4):e12630. PubMed ID: 32698246 [TBL] [Abstract][Full Text] [Related]
20. The role of complement inhibition in kidney transplantation. Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]